Hexagon Capital Partners’s Takeda Pharmaceutical TAK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $176K | Buy |
11,360
+2,662
| +31% | +$41.2K | 0.04% | 69 |
|
|
2025
Q1 | $129K | Buy |
8,698
+3,008
| +53% | +$44.7K | 0.02% | 274 |
|
|
2024
Q4 | $75.3K | Buy |
5,690
+1,271
| +29% | +$16.8K | 0.01% | 383 |
|
|
2024
Q3 | $62.8K | Buy |
4,419
+1,129
| +34% | +$16.1K | 0.01% | 405 |
|
|
2024
Q2 | $42.6K | Sell |
3,290
-1,315
| -29% | -$17K | 0.01% | 468 |
|
|
2024
Q1 | $64K | Sell |
4,605
-15
| -0.3% | -$208 | 0.01% | 380 |
|
|
2023
Q4 | $65.9K | Sell |
4,620
-928
| -17% | -$13.2K | 0.02% | 352 |
|
|
2023
Q3 | $85.8K | Buy |
5,548
+2,199
| +66% | +$34K | 0.02% | 283 |
|
|
2023
Q2 | $52.6K | Sell |
3,349
-907
| -21% | -$14.2K | 0.01% | 349 |
|
|
2023
Q1 | $70.1K | Buy |
4,256
+377
| +10% | +$6.21K | 0.02% | 298 |
|
|
2022
Q4 | $60.5K | Sell |
3,879
-837
| -18% | -$13.1K | 0.02% | 319 |
|
|
2022
Q3 | $61K | Buy |
4,716
+3,569
| +311% | +$46.2K | 0.02% | 331 |
|
|
2022
Q2 | $16K | Buy |
+1,147
| New | +$16K | ﹤0.01% | 584 |
|